Case report shows a rare secondary urethral adenocarcinoma after prostate brachytherapy, highlighting implications for patient monitoring.
Prostate brachytherapy carries a risk of secondary malignancies, with data regarding secondary urethral malignancies being particularly sparse. We report a case of secondary urethral adenocarcinoma presenting 14 years after low-dose-rate (LDR) brachytherapy. A 57-year-old man developed recurrent urethral stenosis after LDR brachytherapy for prostate cancer (2009). In 2023, subsequent resections confirmed HER2-positive, ERBB2-amplified urethral adenocarcinoma. After neoadjuvant oxaliplatin/capecitabine (CAPOX) therapy, he underwent cystoprostatectomy, urethrectomy, and ileal conduit. Pathology showed stage IIIB disease with negative margins. This case underscores a rare but severe complication of prostate brachytherapy, contributing to the clinical understanding of secondary urethral malignancies.
No takes yet. Share an insight, caveat, or question.
Callahan et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: